The experience of treatment of patients suffering from medium and severe acne with the use of isotretinoin

N V Kungurov,M M Kokhan,O V Shabardina

doi:10.25208/vdv606

Abstract

Ural Research Institute of Dermatovenerology and Immunopathology, Ekaterinburg, Russia Shherbakova street 8, 620076, Ekaterinburg, Russia Objective: assessment of the clinical efficacy and safety of the treatment of patients suffering from acne of different forms of severity with the use of isotretinoin (Acnecutan). Materials and methods. Thirty-two patients with acne underwent treatment and made up 3 groups: 11 patients with the moderate to severe form of acne, 12 patients with the severe form of acne, and 9 patients with acne conglobata. The Basic Acne Severity Index (BASI) was used to assess objective manifestations of the disease. Results: As a result of treatment, the BASI reduced in patients with moderate to severe acne from 25.1 ± 1.6 to 1.5 ± 0.7, in patients with severe acne - from 31.5 ± 2.0 to 1.3 ± 0.8, with acne conglobata - from 45.3 ± 5.2 to 2.8 ± 0.7. Adverse effects that were recorded (such as skin dryness and xerosis, cheilitis and retinoid dermatitis, increased ASAT and ALAT levels in the blood serum) were eliminated with the use of skin care products or by reducing the drug dose. Conclusion: The authors demonstrated high efficacy and safety of Acnecutan in the treatment of patients suffering from acne vulgaris.

Highlights

The experience of treatment of patients suffering from medium and severe acne with the use of isotretinoin
Objective: assessment of the clinical efficacy and safety of the treatment of patients suffering from acne of different forms of severity with the use of isotretinoin (Acnecutan)
As a result of treatment, the Basic Acne Severity Index (BASI) reduced in patients with moderate to severe acne from 25.1 ± 1.6 to 1.5 ± 0.7, in patients with severe acne – from 31.5 ± 2.0 to 1.3 ± 0.8, with acne conglobata – from 45.3 ± 5.2 to 2.8 ± 0.7

Summary

Опыт терапии больных среднетяжелыми и тяжелыми акне препаратом изотретиноин

ФГБУ «Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии» Минздрава России, Екатеринбург 620076, г. Оценка клинической эффективности и безопасности терапии больных акне различной степени тяжести препаратом изотретиноин (Акнекутан*). В процессе лечения индекс ОТУ снизился у больных со среднетяжелыми акне с 25,1 ± 1,6 до 1,5 ± 0,7 балла, с тяжелыми акне — с 31,5 ± 2,0 до 1,3 ± 0,8 балла, с конглобатными акне — с 45,3 ± 5,2 до 2,8 ± 0,7 балла. Показана высокая эффективность и безопасность препарата Акнекутан в терапии больных вульгарными акне. Objective: assessment of the clinical efficacy and safety of the treatment of patients suffering from acne of different forms of severity with the use of isotretinoin (Acnecutan). Results: As a result of treatment, the BASI reduced in patients with moderate to severe acne from 25.1 ± 1.6 to 1.5 ± 0.7, in patients with severe acne – from 31.5 ± 2.0 to 1.3 ± 0.8, with acne conglobata – from 45.3 ± 5.2 to 2.8 ± 0.7. Conclusion: The authors demonstrated high efficacy and safety of Acnecutan in the treatment of patients suffering from acne vulgaris

Вестник дерматологии и венерологии

Findings

Материал и методы